Congenital Adrenal Hyperplasia Clinical Trial
Official title:
Surgical Evaluation Of Using The Inner Surface Of The Prepuce In Feminizing Genitoplasty In Cases Of Verilized Females With Congenital Adrenal Hyperplasia
Verified date | December 2019 |
Source | Kasr El Aini Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background and Rationale: The vaginoplasty remains a challenge for the surgeon. The most
commonly used techniques have been: the Y-V plasty described by fortunoff for low vagina, the
pullthrough operation described by Hendren and Crawford for high vagina, and the
passerini-Glazer technique . None of these procedures is entirely satisfactory; with the
first two, the neovagina has a tendency to become stenotic in most cases. Moreover, in the
third, in addition to the high rate of stenosis, which is encountered in a third of case ,
the high rate of urethro-vaginal fistulas is unacceptable
Objectives :
To describe and evaluate a surgical technique for vaginoplasty that is easy to realize with
fewer complications especially vaginal stenosis.
Study population & Sample size : 24 patients suffering from congenital adrenal hyperplasia
(CAH) presenting to outpatient clinic of diabetis Endocrine And Metabolism Pediatric Unit
(DEMPU) of Cairo University Specialized Pediatric Hospital will be considered.
Study Design : non-controlled prospective clinical trial with all patients included in single
group
Methods: Cystoscopy will be done promptly before proceeding to surgery, Confluence depth more
than 20 mm is considered high anomaly, feminizing genitoplasty will be done as a one-stage
procedure, One month after operation, examination under anesthesia will be done with
calibration of vagina.
Possible Risk (s) to study population : The risk of this study is involving a vulnerable
group of females which exposed to lengthy operation may complicate with bleeding and need for
blood transfusion, infection early after surgery or vaginal stenosis.
Outcome parameter (s):
Vaginal calibration using hegars dilators Urodynamics for females older than 3 years and
complaining from incontinence
Status | Recruiting |
Enrollment | 5 |
Est. completion date | January 1, 2020 |
Est. primary completion date | January 1, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Months to 14 Years |
Eligibility |
Inclusion criteria: - Females (46, XX genotype identified by karyotype - Age: infants and children from 18 months old age to 14 years - Virilized external genitalia. - Persistent urogenital sinus - Congenital adrenal hyperplasia. - Controlled by glucocorticoid and mineralocorticoid replacement therapy and clinically and hormonally judged fit for surgical interventions. - Voluntarily provided informed written consent of the parents for the planned procedure and possible risks. - Informed written approval of the parents of the included children to use clinical data collected in a research program. Exclusion Criteria: - Male disorders of sexual development (46 XY) - Debatable sex of rearing; Mixed gonadal dysgenesis, Ovotesticular disorders of sexual development and partial androgen insensitivity syndrome. - Inadequate compliance with corticosteroid therapy, rendering surgery or interventions clinically hazardous or unsuitable. - Inadequately controlled hormonal assay: elevated androgens. - Patients who did any corrective surgery before. |
Country | Name | City | State |
---|---|---|---|
Egypt | faculty of medicine- Cairo University | Cairo | El Manial |
Lead Sponsor | Collaborator |
---|---|
Kasr El Aini Hospital |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | vaginal size calibration | the new vagina will be assessed for stenosis 1 month after the procedure using Hegar dilators under general anaesthesia, further calibration will be done over 6 months to ensure patency of the vagina and to avoid stenosis by dilatation if stenosis encountered | 6 months to one year | |
Secondary | urinary incontinence | in patient older than 3 years and complaining from incontinence, urodynamics will be done. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03687242 -
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
|
Phase 2 | |
Active, not recruiting |
NCT04544410 -
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
|
Phase 2 | |
Not yet recruiting |
NCT04087148 -
Linear Growth of Children With Congenital Adrenal Hyperplasia
|
||
Completed |
NCT03162159 -
Adult Height Prediction in Congenital Adrenal Hyperplasia
|
||
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Enrolling by invitation |
NCT05162950 -
Effects and Importance of Epinephrine/Adrenalin Deficiency in CAH
|
||
Withdrawn |
NCT03532022 -
Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy
|
Phase 3 | |
Recruiting |
NCT02795871 -
Prenatal Dex Study
|
N/A | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
Recruiting |
NCT04903587 -
Gonadal Changes In Congenital Adrenal Hyperplasia Patients
|
||
Not yet recruiting |
NCT04536662 -
Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency
|
Phase 4 | |
Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
Active, not recruiting |
NCT04490915 -
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
|
Phase 3 | |
Completed |
NCT01807364 -
Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia
|
N/A | |
Completed |
NCT02804178 -
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
|
Phase 2 | |
Completed |
NCT03019614 -
An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone
|
Phase 1 | |
Not yet recruiting |
NCT04293133 -
Final Height in Patients With CAH
|
||
Recruiting |
NCT05663320 -
A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia
|
N/A | |
Active, not recruiting |
NCT04806451 -
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
|
Phase 3 | |
Completed |
NCT01875640 -
Decision Support for Parents Receiving Information About Child's Rare Disease
|